May 2026
đź“Ł VC round data is live. Check it out!
Largest BioTech Public Companies in the UK
Benchmark revenue and EBITDA valuation multiples for public comps like
AstraZeneca, GSK, Haleon, Roivant Sciences and Centessa Pharmaceuticals.
 | A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales. | $186 | +34% | $288B | $314B | 5.3x | 16.1x | ||
| In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV. | $25 | +36% | $102B | $123B | 2.7x | 8.1x | ||
| Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition. | $5 | -9% | $40B | $50B | 3.3x | 13.0x | ||
| Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. | $29 | +158% | $21B | $17B | 2025.7x | (17.8x) | ||
| Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors. | $40 | +203% | $6B | $6B | 400.5x | (32.8x) | ||
| Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world. | $20 | -25% | $4B | $6B | 1.7x | 6.6x | ||
| Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development. | $31 | +15% | $2B | $2B | 2.6x | 14.5x | ||
| Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. | $2 | +5% | $2B | $2B | 5.3x | (13.7x) | ||
| Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distribution of branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Scandinavia, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom. | $10 | -40% | $1B | $4B | 1.1x | 6.1x | ||
| Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. | $8 | +100% | $1B | $1B | 4.8x | 336.1x | ||
| MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. | $10 | +50% | $908M | $924M | 11.3x | (10.3x) | ||
| Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK). | $0 | +14% | $767M | $789M | 10.7x | (24.1x) | ||
| Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea. | $1 | +157% | $484M | $481M | 3164.6x | (14.4x) | ||
| International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made. | PE & VC+1 | $13 | +69% | $423M | $466M | (1979.6x) | - | |
| Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans. | $0 | +153% | $334M | $344M | 53.8x | (20.1x) | ||
| Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States. | $5 | -35% | $317M | ($228M) | (3.1x) | 1.1x | ||
| Animalcare Group PLC is active in the healthcare division in the United Kingdom. It is a generic veterinary medicines company. The company mainly caters to veterinary professionals in the treatment of companion animals through a product line comprised of licensed veterinary medicines and companion animal identification products and services. Its only reportable segment is Pharmaceutical which includes the development and marketing of pharmaceutical products. The company has a presence in Belgium, The Netherlands, Germany, Italy, Portugal, the European Union - Other, Asia, Middle East Africa, Spain, the United Kingdom, and Other Countries of which Spain derives the majority of the revenue to the company. | $4 | +14% | $309M | $326M | 2.7x | 13.5x | ||
| Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs. | $3 | -34% | $150M | $80M | 143.6x | (0.9x) | ||
| Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country. | $23 | -39% | $118M | $111M | 6.3x | 8.1x | ||
| 4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States. | $7 | -46% | $110M | $87M | 69.3x | (5.9x) | ||
| Agronomics Ltd is an Isle of Man-based investment firm. The company mainly invests in the nascent industry of modern foods, which are environmentally friendly alternatives to the traditional production of meat and plant-based sources of nutrition. | $0 | -- | $102M | $99M | (6.2x) | (2.8x) | ||
| OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain. | $2 | -34% | $89M | $85M | - | (11.9x) | ||
| Eco Animal Health Group PLC is an animal health biotech company. It provides quality products for swine and poultry, anti-infectives to treat illness, improve health, and performance. Its products include Aivlosin/Valosin Solutions and Parasite Solutions. The company’s segments include Corporate/UK, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World, with the majority of the revenue deriving from China and Japan. | $1 | +56% | $86M | $68M | 0.6x | 6.9x | ||
| Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group’s main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment. | $0 | +93% | $86M | $104M | 2.1x | (12.1x) | ||
| Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). | $0 | -89% | $49M | $8M | 16.7x | (0.2x) | ||
| Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world. | $0 | -- | $41M | $37M | 3.2x | (10.8x) | ||
| Eden Research PLC is a UK-based company that develops and supplies biopesticide products and natural microencapsulation technologies to the crop protection, animal health, and consumer products industries. It operates through Agrochemical, Consumer products, and Animal health segments. It offers a range of product categories under Foliar Diseases Control, Soil Pest, Protected Glass House Crops, Vascular Diseases Control, and Post-Harvest Applications. | $0 | -7% | $37M | $36M | 6.1x | (16.7x) | ||
| Carclo PLC is a technology-led plastics group that is engaged in three segments: CTP, Aerospace, and Central. The CTP segment supplies value-adding engineered solutions for the life sciences, optical, and precision component industries. This business operates internationally in a fast-growing and dynamic market underpinned by rapid technological development. The Aerospace segment supplies systems to the manufacturing and aerospace industries. The Central segment relates to central costs and non-trading companies. Geographically, it operates in the regions of the UK, Rest of Europe, North America and Rest of the world. | $0 | -- | $35M | $67M | 0.4x | 3.0x | ||
| Provexis PLC is engaged in developing, licensing and selling the proprietary, scientific Fruitflow heart-health functional food ingredient for the global functional food sector. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats. | $0 | +36% | $33M | $32M | 18.7x | (53.3x) | ||
| Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines. | $1 | -27% | $28M | ($27M) | - | 0.4x | ||
| Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union. | $0 | -92% | $5M | $507K | 0.0x | 0.3x | ||
| GenIP PLC is engaged in Generative Artificial Intelligence (GenAI), and empowers organizations to evaluate and commercialize technology discoveries through two distinct to providing bespoke enhanced research reports assessing the market potential for new technological innovations by using the GenAI-driven proprietary software, InventionEvaluator, and providing executive recruitment services to match technology organizations with experienced executives and business leaders using the GenAI-driven proprietary software, Vortechs. Its operating segments are Invention Evaluator and Vortechs. It generates the majority of its revenue from the Invention Evaluator segment. | $0 | -84% | $2M | $1M | 10.0x | (1.5x) | ||
| Median | $3 | +14% | $313M | $218M | 5.0x | (0.9x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.